Patents by Inventor Mark A. Dombrowski

Mark A. Dombrowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Benzamide inhibitors of the P2Xreceptor
    Patent number: 7671053
    Abstract: The present invention provides benzamide inhibitors of the P2X7 receptor of the formula: wherein R1-R3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: March 2, 2010
    Assignee: Pfizer, Inc.
    Inventors: Mark A. Dombrowski, Allen J. Duplantier
  • Benzamide inhibitors of the P2Xreceptor
    Patent number: 7553972
    Abstract: The present invention provides benzamide inhibitors of the P2X7 receptor of the formula: wherein R1-R3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.
    Type: Grant
    Filed: February 9, 2007
    Date of Patent: June 30, 2009
    Assignee: Pfizer, Inc.
    Inventors: Mark A. Dombrowski, Allen J. Duplantier, Chakrapani Subramanyam
  • Benzamide inhibitors of the P2Xreceptor
    Patent number: 7407956
    Abstract: The present invention provides benzamide inhibitors of the P2X7 receptor of the formula: wherein R1-R3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.
    Type: Grant
    Filed: January 8, 2007
    Date of Patent: August 5, 2008
    Assignee: Pfizer, Inc.
    Inventors: Mark A. Dombrowski, Allen J. Duplantier